The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease.

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for ...

Biogen and Eisai have won Food and Drug Administration approval of an intravenous maintenance dosing of their Leqembi drug for early Alzheimer's disease. The companies late Sunday said the FDA ...

The recent approvals of Leqembi (lecanemab) and Kisunla (donanemab) have refreshed the landscape of Alzheimer’s disease treatments. For the first time, patients have the option to take a drug that ...

While you'd be forgiven for confusing the upcoming "A Quiet Place Part III" with the franchise's third entry, the prequel "A Quiet Place: Day One," a proper follow-up continuing the Abbott family ...

Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk of disease progression or death by 27% in patients with previously ...

A tree nut allergy occurs when a person cannot eat a certain type of nut because their immune system deems certain proteins found within it as harmful. This causes a reaction that can come with mild ...

What’s inside this Plumpy’Nut® sachet that has saved millions of children? Plumpy’Nut®, also known as ready-to-use therapeutic food (RUTF), is a high-energy peanut paste containing sugar, vegetable ...

BioArctic AB (publ) announced that the US Food and Drug Administration (FDA) has accepted BioArctic’s partner Eisai’s Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) ...